BPOM Elevated to WHO Listed Authority Status, Indonesian Vaccine Credibility Could Reach Developed Nation Standards

BPOM Elevated to WHO Listed Authority Status, Indonesian Vaccine Credibility Could Reach Developed Nation Standards

Jakarta, CNBC Indonesia – CNBC Indonesia held a Health Forum with the theme “BPOM Achieves WLA Status, What Are the Benefits for Business Players?” which provided comprehensive coverage of the impact of Indonesia’s drug and food regulatory authority, the State Administration of Drug and Food Control (BPOM), obtaining recognition from the global health agency and entering the WHO Listed Authority (WLA) register.

William Adi Teja, Deputy for Drug, Narcotics, Psychotropic, Precursor and Addictive Substance Supervision at BPOM, stated that BPOM obtained WLA status by successfully meeting nine criteria set by the WHO, including efficiency and the integrity of BPOM in evaluating pharmaceutical and vaccine products entering Indonesia, which now meets the standards of developed nations.

BPOM will continue to maintain and preserve its WLA status, which is reviewed every five years. From the business sector perspective, Shadiq Akasya, Director General of Bio Farma, described BPOM’s achievement as global recognition of the quality equivalence of Indonesian products with world-class products. This development will also drive efficiency and facilitate the development and export of Indonesian pharmaceutical products.

For vaccine manufacturers, FX Sudirman, Director General of Biotis Pharmaceuticals Indonesia, stated that BPOM’s achievement will support the development of domestic vaccines, particularly regarding the credibility of Indonesian products reaching developed nation standards.

Additionally, Andreas Donny Prakasa, Director of Corporate Relations and Strategic Affairs at PT Etana Biotechnologies Indonesia, noted that the elevation of BPOM’s status has major implications for the biopharmaceutical industry as it can boost confidence levels among pharmaceutical and vaccine manufacturers whilst enhancing the competitiveness of Indonesian products.

The Health Forum discussion, moderated by Shafinaz Nachiar, brought together BPOM Deputy William Adi Teja, Bio Farma Director General Shadiq Akasya, Biotis Pharmaceuticals Indonesia Director General FX Sudirman, and PT Etana Biotechnologies Indonesia’s Andreas Donny Prakasa to discuss the impact of BPOM’s new status on pharmaceutical business players.